Project Grant R01CA292818
Award Date
6/9/25
Completion Date
5/31/30
Dollars Obligated
$619K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This National Cancer Institute (NCI) Project Grant award under CFDA 93.396 - Cancer Biology Research provides $552,874 in funding to The Regents of the University of California, San Francisco (UCSF) from August 1, 2024 to July 31, 2029. The project aims to dissect the cellular and molecular pathways by which the A20 protein regulates anti-tumor immunity. Specifically, the research will focus on understanding how A20, a potent regulator of immune homeostasis, restrains both acute and anamnestic...
This federal Project Grant award of $441,202.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the role of ex-regulatory T cells (ex-Tregs) in autoimmunity and cancer immunity. The research aims to utilize a genetic Treg lineage tracing system to monitor ex-Tregs and test whether they are required for tumor control or the onset of autoimmune disease when...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $276,450 to The Salk Institute for Biological Studies to investigate the role of the PPARD/CIITA/MHCII axis in regulating regulatory T cell (Treg) function and its impact on tumor immunity. The key objectives are to: 1) define the molecular mechanisms by which MHCII expression in Tregs is regulated by the PPARD/CIITA...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $571,496 Project Grant to the University of Toledo Health Science Campus Division to conduct research aimed at understanding the mechanisms by which the tumor-intrinsic TAZ expression regulates the tumor microenvironment and immune suppressive cells like myeloid-derived suppressor cells (MDSCs) in triple-negative breast cancer (TNBC). The research project, titled "Dissecting Molecular Mechanisms of Tumor-Induced...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $509,448 to The Leland Stanford Junior University to investigate strategies for reprogramming antigen-presenting cells in lymph nodes to overcome tumor-induced immune tolerance and metastatic progression. The research aims to: 1) Identify the antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development in lymph nodes, and 2) Assess...
This $226,504 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the Rector & Visitors of the University of Virginia aims to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The research will use a mouse genetic model to study immune responses during pre-malignant cancer progression, focusing on characterizing the functional state of B and T cells within these novel...
The National Cancer Institute (NCI) awarded a $532,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Icahn School of Medicine at Mount Sinai. The grant, effective April 1, 2025 through March 31, 2030, will fund research to define the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that promote anti-tumor immunity and enhance responses to PD-1 targeted immunotherapy. The project aims to study the transcriptional programs and secreted...
The U.S. National Cancer Institute (NCI) awarded a $626,534 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Medical University of South Carolina (MUSC) to support a 5-year research project titled "Dissecting the Mechanism for Transient ER Stress-Induced Anti-Tumor T Cell Response." The project aims to investigate how transient endoplasmic reticulum (ER) stress can improve the function and anti-tumor efficacy of T cells, particularly through modulating mitochondrial...
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...
This $674,996 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to determine if targeting the PSGL-1 checkpoint inhibitor can promote the development and/or maintenance of CD8+ T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade (ICB) therapy. The key objectives are to evaluate if PSGL-1 blockade can generate or sustain tumor-specific...